LifeMD, Inc. (LFMD) stock intrinsic value fair value estimate & owner earnings analysis

LifeMD runs a direct-to-consumer virtual care business. Patients pay a subscription to see licensed clinicians online and have prescriptions delivered at home through partner pharmacies. Its programs cover weight management (GLP-1 medicines), men's health and testosterone, women's health and menopause, dermatology and primary care. At the end of June 2026 it had about 356,000 active subscribers, roughly 108,000 of them in the weight management program, and about 84% of revenue was recurring. In November 2025 it sold its majority stake in WorkSimpli, its legal-document software business, booking a $21.3 million gain. It had already repaid its Avenue term loan in August 2025. What remains is a telehealth-only company with no borrowings, a $30 million revolving credit line from Citizens Bank that has not been drawn, and $35 million of 8.875% perpetual Series A preferred stock that ranks ahead of the common shares. How we measure earnings. We start with cash from operations, then remove short-term working-capital swings, subtract stock-based compensation in full, and subtract the spending needed to keep the platform running. At LifeMD that spending is mostly software development the company capitalizes, about $7.6 million in 2025. We count only the part not explained by revenue growth, and when revenue falls we count all of it. For the telehealth business as it exists today (WorkSimpli removed from every year), this measure was a loss of about $20.5 million in 2024 and $8.1 million in 2025. That works out to about -$0.50 and -$0.18 per share before the preferred dividend, or -$0.57 and -$0.25 after it. Earlier years are far worse, but they described either a much smaller supplement business before 2020 or a company still consolidating WorkSimpli. The company has not produced a full year of positive owner earnings in any year we can measure. What changed this year. The improvement through 2025 has reversed. In the first half of 2026 revenue fell to $97.4 million from $99.9 million. The company finished moving weight-management patients off compounded GLP-1 drugs and onto branded ones (about 95% of new patients now start on branded drugs), and it changed pricing, including a $39 introductory offer that cuts upfront cash. Selling and marketing in the second quarter was $28.0 million, 27% higher than a year earlier. Operating cash flow for the half was a $6.5 million outflow. Adjusted for working capital, stock compensation and software spending, the first half lost about $19 million, an annual pace roughly double 2024's loss. Cash fell from $36.8 million at year-end to $25.1 million at June 30. The company missed its bank's interest-coverage test at March 31, 2026; the bank waived it and replaced the test, and from the third quarter the line requires at least $40 million of cash plus unused availability. Three pharmacies now handle 87% of prescription fulfillment. Full-year 2026 guidance was cut from $220-230 million of revenue to $205.5-212.5 million, and the expected full-year adjusted EBITDA swung from a $12-17 million profit to a loss of up to $6 million. Management's adjusted EBITDA excludes stock compensation and software spending, so even its hoped-for fourth-quarter profit would not mean positive owner earnings on our measure. Valuing it. Shareholders own what is left after the preferred stock, so we value the business first and then subtract what ranks ahead of the common. Interest is no longer a factor because the company has no debt. Against the business value we hold about $20 million of cash beyond what operations need. Against it we subtract about $42 million for the preferred: $35 million of liquidation preference, plus an allowance because a perpetual 8.875% dividend costs more than our yardstick for as long as it stays outstanding. We credit no growth in any case. The company has never shown a repeatable, self-funded way to add earnings. Its growth has been bought with heavy marketing and paid for with share issuance (diluted shares rose from about 27 million in 2021 to about 48 million today), and it has not turned into owner profit. Base case. The cost cuts already under way (restructuring charges in the first half, marketing down $1.8 million from the first quarter to the second) and the shift to multi-month prepaid weight-management packages narrow the losses. The business burns about $12 million over the next year and a further $8 million over the following two, then runs at roughly break-even. It earns nothing beyond break-even because it has never shown it can. The business is worth about -$19 million, and after adding $20 million of excess cash and subtracting $42 million for the preferred, the common is worth about -$41 million, roughly -$0.85 per share. On these assumptions the common shares carry about $41 million more in claims and future losses than the business and its spare cash can cover. The gap would most likely be closed by issuing more shares; the company already has about $44.6 million of room on its at-the-market share program. Bear case. Fulfillment depends on three pharmacies. Drugmakers now sell GLP-1s straight to patients through their own channels, and Eli Lilly and Novo Nordisk both do. Paid-acquisition businesses lose ground fast when advertising costs rise, as LifeMD's 27% rise in marketing on falling revenue already shows. In this case first-half 2026 losses continue for another year, about $30 million, before cost cuts bring them down over three more years. That is roughly $60 million of business value lost. With the same cash and preferred, the common is worth about -$1.69 per share. Cash runs out inside the first year, so this case requires heavy dilution at low prices or drawing the revolver. The revolver's $40 million liquidity test would restrict that. Bull case. The pricing reset and the branded-drug transition work as intended. The fourth-quarter revenue and margin step-up the company has described arrives on time, the new XYOSTED testosterone partnership adds to men's health, and the business reaches about $10 million a year of cash before the preferred dividend from 2028. That is about $0.20 per share, roughly in line with the best two quarters the telehealth business has shown. It holds that level through the decade and fades over the following ten years, since we have no evidence of durability beyond that. The business would be worth about $73 million, and the common about $1.05 per share. Accounting judgements. We removed swings in deferred revenue and accrued expenses as timing items. They added $17 million to 2024 cash flow and took $8 million from 2025, which shows they are not earnings. We subtracted stock compensation in full and treated the preferred stock as a senior claim, not as equity. We could not reconcile one item: the filings do not split software spending between upkeep and new features, so the upkeep share is estimated from the link between that spending and revenue growth. Margin-of-safety price. We are not confident in the earnings level, and there is none to anchor on. The telehealth business has lost money on our measure in every year we can see, and 2026 is running worse than 2025. The worst plausible outcome is a pharmacy-partner disruption or drugmakers cutting telehealth out of GLP-1 distribution while cash is already short. It would hit a business that owns no hard assets, carries a preferred stock ranking ahead of the common, and would have to issue shares at depressed prices. Common holders would then be heavily diluted or left with little. If we are wrong about the cost cuts, the losses run longer than the base case and the deficit grows. If we are wrong in the other direction, the bull case still gives only about a dollar a share. The business pays common holders nothing while waiting. On today's evidence no margin-of-safety price is supportable, because the base and bear cases put the common below zero. A margin-of-safety price applies only after the business proves it can fund itself: four consecutive quarters of positive owner earnings, after full stock compensation and software spending, with no new shares issued. If that happened, the business would look like the bull case, worth about $1 a share. For a 20% annual return from a newly profitable subscription business with a senior preferred, the margin-of-safety price would be no more than about $0.50 a share. That price allows for the bull case being only partly right, for the common sitting behind about $42 million of preferred, and for several years of waiting with no dividend. Our previous estimate valued the shares well above today's figures. Those numbers were built on a different basis and are not comparable. The business has also deteriorated since then: revenue is now falling, losses are wider, the bank covenant was missed, and full-year guidance was cut sharply in August 2026.